To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Certolizumab pegol (CDP870) (proposed tradename Cimzia) is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody.
Additional recommended knowledge
Positive results have been demonstrated in two phase III trials (PRECiSE 1 and 2) of certolizumab pegol vs placebo in moderate to severe active Crohn's disease.
In addition, data from both trials suggest it is well-tolerated. As yet its efficacy has not been directly compared to other anti-TNF-alpha agents.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Certolizumab_pegol". A list of authors is available in Wikipedia.|